0

Cannabinoid-1 Receptor Neutral Antagonist Reduces Binge-Like Alcohol Consumption and Alcohol-Induced Accumbal Dopaminergic Signaling

Andrea Balla, Bin Dong, Borehalli M Shilpa, Kiran Vemuri, Alexandros Makriyannis, Subhash C Pandey, Henry Sershen, Raymond F Suckow, K Yaragudri Vinod

Neuropharmacology. 2018 Mar 15;131:200-208.

PMID: 29109060

Abstract:

Binge alcohol (ethanol) drinking is associated with profound adverse effects on our health and society. Rimonabant (SR141716A), a CB1 receptor inverse agonist, was previously shown to be effective for nicotine cessation and obesity. However, studies using rimonabant were discontinued as it was associated with an increased risk of depression and anxiety. In the present study, we examined the pharmacokinetics and effects of AM4113, a novel CB1 receptor neutral antagonist on binge-like ethanol drinking in C57BL/6J mice using a two-bottle choice drinking-in-dark (DID) paradigm. The results indicated a slower elimination of AM4113 in the brain than in plasma. AM4113 suppressed ethanol consumption and preference without having significant effects on body weight, ambulatory activity, preference for tastants (saccharin and quinine) and ethanol metabolism. AM4113 pretreatment reduced ethanol-induced increase in dopamine release in nucleus accumbens. Collectively, these data suggest an important role of CB1 receptor-mediated regulation of binge-like ethanol consumption and mesolimbic dopaminergic signaling, and further points to the potential utility of CB1 neutral antagonists for the treatment of binge ethanol drinking.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP614726851 AM4113 AM4113 614726-85-1 Price
qrcode